XXB750 / Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
XXB750 / Novartis
2021-005738-41: An efficacy, safety, tolerability and dose finding study of XXB750 in resistant hypertension patients Estudio de búsqueda de dosis para evaluar la eficacia, la seguridad y la tolerabilidad de XXB750 en pacientes con hipertensión resistente

Not yet recruiting
2
170
Europe, RoW
-, XXB750, Concentrate for solution for injection
Novartis Farmacéutica, S.A., Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Pharma AG
Resistant hypertension Hipertensión resistente, Resistant hypertension Hipertensión resistente, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Recruiting
2
720
Europe, Japan, US, RoW
Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
Novartis Pharmaceuticals
Heart Failure
10/25
12/25
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Active, not recruiting
2
192
Europe, Japan, US, RoW
Experimental drug, Placebo
Novartis Pharmaceuticals
Resistant Hypertension
07/24
08/24

Download Options